China-Max-Anl-Auto-Fuse-Golden-

Empagliflozin API And Intermediates

Empagliflozin is an orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.

Our Empagliflozin Intermediates is as following,we have all the below API and intermedites offering all year.

Empagliflozin API cas 864070-44-0,Empagliflozin Cas 915095-89-5,

Empagliflozin Cas 915095-86-2,Empagliflozin Cas 915095-84-0,

Empagliflozin Cas 915095-85-1,Empagliflozin Cas 915095-86-2,Empagliflozin Cas 915095-87-3,

Empagliflozin Cas 915095-94-2,Empagliflozin Cas 915095-99-7,Empagliflozin Cas 864070-44-0

Empagliflozin API cas 864070-44-0,Empagliflozin Cas 915095-89-5,Empagliflozin Cas 915095-86-2,Empagliflozin Cas 915095-84-0

 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com